Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol-Myers Squibb cites own "expert panel" to support caffeine GRAS/E status.

This article was originally published in The Tan Sheet

Executive Summary

BRISTOL-MYERS CITES OWN "EXPERT PANEL" TO SUPPORT CAFFEINE GRAS/E STATUS in an Aug. 21 letter to FDA submitted by the company's law firm Kleinfeld, Kaplan and Becker. Bristol-Myers Squibb argues in the letter that caffeine should be designated generally recognized as safe and effective for use as an analgesic adjuvant with acetaminophen. FDA announced in April 18 "feedback" letters to analgesic manufacturers, including BMS, that caffeine will be allowed as an analgesic adjuvant with aspirin and aspirin/acetaminophen combinations in the external analgesic final rule adjuvant, but will not be permitted with acetaminophen alone ("The Tan Sheet" May 8, p. 1).
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084245

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel